Management Team 2020-03-27T15:22:10+01:00

Management Team

Anders Rylander (1970)CEO since 2010
Anders Rylander has an MSc in Mechanical Engineering with specialties in Industrial Economics and Management from the Swedish Royal Institute of Technology. He has been a management consultant for more than 15 years, at companies such as Accenture and Andersen Consulting. Anders co-founded Axholmen, a management consulting firm that focuses on improving the operational efficiency of large corporations in the Nordic market. He also founded Arinvest, a private equity investment firm investing in the clean-tech and life science business areas.

Holdings: 3 575 640 A-shares, 368 956 B-shares, 20 000 warrants 2019/2022 (TO5)

Cecilia Driving (1971)CFO since 2016
Cecilia holds a LLM and BSc in Business Administration from Stockholm University. She has held several CFO positions in life-science, private equity, research and telecom companies. She also serves as Chairman of Adom AB.

Holdings: 10 000 B-shares, 20 000 warrants 2017/2020 (TO2), 20 000 warrants 2018/2021 (TO3), 20 000 2019/2022 (TO5)

Otti Bengtsson Gref (1968)R&D Director from 2020
Otti holds a Med Lic in Immunology from Uppsala University and an Executive MBA from MGruppen. She has more than 20 years of experience working within academic research and product development within the biomedical industry. She has had several management positions within both product development and production within Thermo Fischer and has an extensive experience of product development and production of In Vitro Diagnostic. Assay. Previously, Otti served as Research and Development Director at Cavidi that develops, manufactures and markets molecular diagnostic products within the HIV area.

Holdings: 20 000 warrants 2019/2022 (TO5)

Henrik Winther (1966)SVP Business Development from 2020
Henrik has a background as associate professor in anatomy, physiology and cell biology at the University of Copenhagen before moving over to the industry and Danish diagnostic company Dako that were later acquired by Agilent. At Dako, Henrik held numerous management positions. He was R&D Director before heading up the Companion Diagnostics Business Area. Under Henriks leadership, the business area had a tenfold growth both in terms of revenue and headcount. At Agilent, Henrik was appointed Vice President and General Manager of Companion Diagnostics Division. Previous to joining Biovica, Henrik had the role as SVP Business Development
at Swedish diagnostic company Immunovia.

Holdings: 20 000 warrants 2019/2022 (TO5)

Robert Dann (1962)SVP Marketing and US Business since 2020
Robert Dann holds an MA in Russian Civilization from the University of Chicago, and an MBA from Columbia University. He has over 20 years’ experience in the healthcare industry, in roles spanning country management, global product launches, and strategy. He has concentrated strongly on cancer care, working on therapeutics, diagnostics, and artificial intelligence applications at AstraZeneca, GE Healthcare, and IBM Watson Health, and has been involved in bringing many breakthrough healthcare innovations into practice.

Holdings: none

Adam Germunder (1984)Operations Director since 2017
Adam holds a BSc in Mechanical Engineering from Uppsala University.
Adam has experience from production management and process development in the life science business. Before joining Biovica Adam worked as a production manager at Fiomi Diagnostics AB and as teamleader at Fresenius Kabi.

Holdings: 4 600 B-shares, 20 000 warrants 2018/2021 (TO3), 20 000 warrants 2019/2022 (TO5)

Wing Cheng, Ph.D. (1974)Market Access and Quality Assurance Director since 2018
Wing Cheng received a Ph.D. in Clinical Immunology and a Master of Science in Molecular Biotechnology from Uppsala University. Wing has held leading positions within the Regulatory and Reimbursement area from Competent Authorities e.g The Dental and Pharmaceutical Benefits Agency (TLV), the Medical Products Agency (MPA), European Medicine Agency (EMA) and the European Commission. Previously he served as Manager Clinical Utility at Thermo Fisher Scientific.

Holdings: 3 700 B-shares, 20 000 warrants 2018/2021 (TO3), 20 000 warrants 2019/2022 (TO5)